XBiotech Inc. Files 10-K/A Amendment

TL;DR

<b>XBiotech Inc. has filed an amendment to its 2023 annual report, providing updated information for its common stock trading on NASDAQ.</b>

AI Summary

XBiotech Inc. (XBIT) filed a Amended Annual Report (10-K/A) with the SEC on April 24, 2024. XBiotech Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company's common stock trades on the NASDAQ Global Select Market under the symbol XBIT. XBiotech Inc. is incorporated in British Columbia, Canada. The principal executive offices are located at 5217 Winnebago Lane, Austin, TX 78744. The filing was made on April 24, 2024.

Why It Matters

For investors and stakeholders tracking XBiotech Inc., this filing contains several important signals. This amendment indicates that XBiotech Inc. is providing updated or corrected information for its fiscal year 2023, which could impact investors' understanding of its financial and operational status. As a company whose stock is publicly traded on the NASDAQ, timely and accurate filings are crucial for maintaining investor confidence and regulatory compliance.

Risk Assessment

Risk Level: low — XBiotech Inc. shows low risk based on this filing. The filing is an amendment to a previous report, suggesting it's for clarification or correction rather than indicating new material negative events.

Analyst Insight

Review the specific changes made in this 10-K/A filing to understand any updated financial or operational details for XBiotech Inc.

Key Numbers

• 2023-12-31 — Fiscal Year End (Report period)
• 2024-04-24 — Filing Date (Date of amendment filing)
• 001-37437 — Commission File Number (SEC identifier)

Key Players & Entities

• XBiotech Inc. (company) — Registrant name
• NASDAQ Global Select Market (company) — Exchange where common stock is traded
• XBIT (company) — Trading symbol
• 5217 Winnebago Lane, Austin, TX 78744 (location) — Principal executive offices address
• 2023 (date) — Fiscal year end
• 2024-04-24 (date) — Filing date

FAQ

Industry Context

XBiotech Inc. operates in the pharmaceutical preparations industry, focusing on the development of therapeutic products.

Regulatory Implications

The company is subject to SEC regulations for public companies, including requirements for annual and amended filings like the 10-K/A.

What Investors Should Do

1. Review the full 10-K/A filing for specific details on amendments made.
2. Monitor future filings for any significant updates from XBiotech Inc.
3. Analyze the company's business operations and financial health based on its SEC filings.

Key Dates

• 2023-12-31: Fiscal Year End — The period covered by the amended annual report.
• 2024-04-24: Filing Date — Date the 10-K/A amendment was submitted to the SEC.

Year-Over-Year Comparison

This is an amended filing (10-K/A), indicating updates or corrections to a previously submitted report for the fiscal year 2023.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share XBIT NASDAQ Global Select

Filing Documents

• d714101d10ka.htm (10-K/A) — 285KB
• d714101dex311.htm (EX-31.1) — 2KB
• d714101dex312.htm (EX-31.2) — 2KB
• 0001193125-24-108802.txt (&nbsp;) — 538KB
• xbit-20231231.xsd (EX-101.SCH) — 4KB
• xbit-20231231_cal.xml (EX-101.CAL) — 1KB
• xbit-20231231_def.xml (EX-101.DEF) — 16KB
• xbit-20231231_lab.xml (EX-101.LAB) — 21KB
• xbit-20231231_pre.xml (EX-101.PRE) — 17KB
• d714101d10ka_htm.xml (XML) — 8KB

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 1

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION 11

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 20

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 27

PRINCIPAL ACCOUNTING FEES AND SERVICES

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES 30 PART IV

EXHIBITS, FINANCIAL STATEMENT SCHEDULES

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES 32 EXPLANATORY NOTE This Amendment No. 1 (this "Amendment") amends the Annual Report on Form 10-K for the year ended December 31, 2023 of XBiotech, Inc. (the "Company"), filed with the Securities and Exchange Commission (the "SEC") on March 15, 2024 (the "Original Form 10-K"). The purpose of this Amendment is solely to amend Part III, Items 10 through 14 of the Original Form 10-K to include information previously omitted from the Original Form 10-K in reliance on General Instruction G(3) to Form 10-K which permits the above-referenced Items to be incorporated in the Annual Report on Form 10-K by reference from a definitive proxy statement, if such proxy statement is filed no later than 120 days after December 31, 2023. At this time, the Company is filing this Amendment to include Part III information in our Annual Report on Form 10-K because we do not intend to file a definitive proxy statement within 120 days of December 31, 2023. Accordingly, Part III of the Original Form 10-K is hereby amended and restated as set forth herein. The information included herein as required by Part III, Items 10 through 14 of Form 10-K is more limited than what is required to be included in the definitive proxy statement to be filed in connection with our annual meeting of stockholders. Accordingly, the definitive proxy statement to be filed at a later date will include additional information related to the topics herein and additional information not required by Part III, Items 10 through 14 of Form 10-K. The reference on the cover page of the Original Form 10-K to the incorporation by reference of our definitive proxy statement into Part III of the Original Form 10-K is hereby deleted. Except as stated herein, this Amendment does not reflect events occurring after the filing of the Original Form 10-K and no attempt has been made in this Amendment to modify or update other disclosures as presented in the Original Form 10-K. PA

View Full Filing

View this 10-K/A filing on SEC EDGAR